Profile data is unavailable for this security.
About the company
Getinge AB is a Sweden-based company operating within healthcare sector. The Company provides hospitals and Life Science institutions with products and solutions aimed at improving clinical outcomes and optimizing workflows. The Company’s reporting segments have the following activities: Acute Care Therapies develops solutions for life-sustaining care in acute health conditions. Life Science offers a comprehensive range of equipment, technical expertise and prevention consultation contamination in pharmaceutical production, biomedical research, production of medical equipment and in various laboratory applications. Surgical Workflows offers products and services for the effective disinfection and sterilization of instruments used in operations, operating tables and others hardware for operating rooms and advanced IT systems for efficient and secure workflows in hospitals.
- Revenue in SEK (TTM)34.97bn
- Net income in SEK2.26bn
- Incorporated1990
- Employees11.79k
- LocationGetinge ABLindholmspiren 7,P.O. Box 8861GOETEBORG 417 56SwedenSWE
- Phone+46 35155500
- Fax+46 8295532
- Websitehttps://www.getinge.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitrolife AB | 3.44bn | -5.01bn | 12.10bn | 1.15k | -- | 1.53 | -- | 3.52 | -37.01 | -37.01 | 25.39 | 58.29 | 0.2407 | 3.44 | 5.24 | 2,987,837.00 | -35.09 | -9.46 | -36.79 | -9.86 | 58.24 | 57.81 | -145.74 | -49.19 | 2.73 | 11.33 | 0.169 | -- | -4.68 | 22.53 | -1,077.00 | -- | 68.15 | 6.58 |
| AddLife AB | 10.44bn | 560.00m | 17.41bn | 2.30k | 32.14 | 3.31 | 12.70 | 1.67 | 4.60 | 4.60 | 85.69 | 44.66 | 0.8105 | 3.83 | 5.87 | 4,549,891.00 | 4.36 | 3.82 | 6.05 | 5.80 | 38.09 | 37.80 | 5.38 | 4.66 | 0.6257 | 3.68 | 0.4671 | 31.71 | 1.52 | 14.64 | 122.22 | 1.58 | 22.47 | 0.00 |
| Embla Medical hf | 8.28bn | 743.42m | 18.89bn | 4.19k | 25.21 | 2.36 | 14.68 | 2.28 | 1.22 | 1.22 | 13.62 | 13.05 | 0.5681 | 2.27 | 6.96 | 1,389,003.00 | 5.12 | 4.60 | 6.10 | 5.43 | 62.30 | 62.25 | 9.01 | 7.99 | 0.9445 | 7.22 | 0.3768 | 0.00 | 8.63 | 8.09 | 22.05 | 68.07 | 6.12 | -- |
| Elekta AB (publ) | 17.57bn | 292.00m | 20.33bn | 4.48k | 72.13 | 2.49 | 12.88 | 1.16 | 0.7646 | 0.7646 | 45.97 | 22.11 | 0.5781 | 3.35 | 3.09 | 3,872,796.00 | 0.9511 | 3.48 | 1.70 | 6.21 | 38.17 | 38.22 | 1.65 | 6.02 | 0.7918 | 7.51 | 0.4724 | 92.20 | -0.5685 | 4.29 | -81.80 | -26.22 | 15.56 | 5.92 |
| Ambu A/S | 8.66bn | 774.00m | 28.87bn | 5.43k | 42.24 | 3.81 | 21.98 | 3.33 | 2.04 | 2.04 | 22.85 | 22.64 | 0.8135 | 1.95 | 7.18 | 1,130,201.00 | 7.27 | 4.06 | 8.49 | 4.82 | 60.07 | 59.33 | 8.94 | 5.48 | 1.67 | 20.74 | 0.0845 | 21.23 | 11.98 | 11.10 | 159.15 | 20.37 | -2.24 | 7.17 |
| Asker Healthcare Group AB | 16.41bn | 469.00m | 30.64bn | 4.51k | 41.76 | -- | 24.95 | 1.87 | 1.92 | 1.92 | 54.47 | -- | 1.15 | 5.10 | 9.34 | 5,010,379.00 | 3.37 | -- | 4.36 | -- | 40.43 | -- | 2.94 | -- | 0.9924 | 3.40 | 0.4561 | -- | 11.69 | -- | 77.34 | -- | -- | -- |
| Sectra AB | 2.24bn | 646.40m | 36.51bn | 1.32k | 59.75 | 21.60 | 47.99 | 16.32 | 3.36 | 3.36 | 11.62 | 9.29 | 0.6688 | -- | 3.93 | 1,726,353.00 | 19.32 | 15.75 | 35.74 | 29.92 | 54.43 | 60.29 | 28.89 | 22.41 | -- | -- | 0.0505 | 19.27 | 19.85 | 4.47 | 31.51 | 18.87 | 7.19 | -- |
| Getinge AB | 34.97bn | 2.26bn | 51.64bn | 11.79k | 24.51 | 1.88 | 11.85 | 1.48 | 8.29 | 8.29 | 128.39 | 108.05 | 0.5808 | 2.91 | 5.36 | -- | 3.78 | 4.48 | 4.94 | 5.91 | 47.63 | 47.54 | 6.51 | 7.57 | 0.8595 | 7.05 | 0.2696 | 47.51 | 0.6042 | 3.24 | 37.85 | -6.96 | 4.69 | 9.63 |
| Demant A/S | 32.68bn | 3.37bn | 55.79bn | 26.70k | 16.36 | 3.93 | -- | 1.71 | 11.21 | 7.31 | 108.71 | 46.67 | 0.6423 | 2.19 | 5.94 | 860,208.20 | 6.62 | 8.82 | 8.18 | 12.44 | 75.62 | 75.44 | 10.30 | 12.49 | 1.00 | 5.69 | 0.6791 | 0.00 | 2.46 | 9.69 | -18.09 | 16.13 | 5.16 | -- |
| Coloplast A/S | 39.68bn | 5.68bn | 143.85bn | 16.98k | 27.16 | 7.85 | 18.52 | 3.63 | 17.71 | 17.71 | 123.79 | 61.25 | 0.5743 | 2.38 | 6.12 | 1,625,729.00 | 8.21 | 12.75 | 10.44 | 17.10 | 67.87 | 67.86 | 14.30 | 18.95 | 0.8122 | 9.75 | 0.6451 | 100.37 | 3.12 | 8.49 | -28.03 | -2.83 | 8.92 | 5.02 |
Data as of Feb 10 2026. Currency figures normalised to Getinge AB's reporting currency: Swedish Krona SEK
43.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 02 Jan 2026 | 22.93m | 9.02% |
| AMF Fonder ABas of 05 Sep 2025 | 22.01m | 8.66% |
| Carnegie Fonder ABas of 19 Jan 2026 | 13.56m | 5.34% |
| Swedbank Robur Fonder ABas of 31 Dec 2024 | 9.66m | 3.80% |
| Incentive ASas of 31 Dec 2024 | 8.83m | 3.48% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 8.49m | 3.34% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 8.14m | 3.20% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 6.53m | 2.57% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 31 Dec 2024 | 6.05m | 2.38% |
| Nordea Investment Management ABas of 31 Dec 2025 | 4.77m | 1.88% |
More ▼
Data from 30 Jun 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
